2505: Q&A with Molecule Group CEO Michael Kraftman, and CFO Keith Butcher

Molekule is consolidating its UK ePharmacy platform and shifting to higher-margin direct-to-consumer weight-loss sales before resuming acquisitions in 2027.

• Rebrand complete: Vulcan Two has renamed to Molekule, with subsidiaries, websites and the WebMed clinical platform already switched; PLC name and ticker change (VUL to MOL) expected within days.
• Weight-loss pivot to D2C: Molekule is shifting weight-loss focus from thin-margin B2B (CloudRx) to direct-to-consumer via its new Molecule Clinic, citing shared margins as unviable for both parties.

Themes, sentiment and reasons are AI-written paraphrases, checked so they never quote an episode. They may contain errors. Not investment advice. Episodes remain the property of their creators.